Trial Based Economic Evaluation: Just Another Piece Of Evidence Claxton K Department of Economics and Centre for Health Economics, University of York,

Slides:



Advertisements
Similar presentations
Measurement of Government Output and Productivity for the National Accounts: Interim Report Tony Atkinson.
Advertisements

Technology Appraisal of Medical Devices at NICE – Methods and Practice Mark Sculpher Professor of Health Economics Centre for Health Economics University.
USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,
Dangerous Omissions: The Consequences of Ignoring Decision Uncertainty Karl Claxton Centre for Health Economics*, Department of Economics and Related Studies,
Evidence synthesis of competing interventions when there is inconsistency in how effectiveness outcomes are measured across studies Nicola Cooper Centre.
Bayesian Health Technology Assessment: An Industry Statistician's Perspective John Stevens AstraZeneca R&D Charnwood Bayesian Statistics Focus Team Leader.
When is there Sufficient Evidence? Karl Claxton, Department of Economics and Related Studies and Centre for Health Economics, University of York.
Cost-Effectiveness Using Decision-Analytic Models
Copyright ©2011 Pearson Education
CHAPTER 21 Inferential Statistical Analysis. Understanding probability The idea of probability is central to inferential statistics. It means the chance.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
What role should probabilistic sensitivity analysis play in SMC decision making? Andrew Briggs, DPhil University of Oxford.
VIII Evaluation Conference ‘Methodological Developments and Challenges in UK Policy Evaluation’ Daniel Fujiwara Senior Economist Cabinet Office & London.
Is it time to ban PSA? In support of OFSA… Stirling Bryan, PhD.
Modelling Partially & Completely Missing Preference-Based Outcome Measures (PBOMs) Keith Abrams Department of Health Sciences, University of Leicester,
Populating decision analytic models Laura Bojke, Zoë Philips With M Sculpher, K Claxton, S Golder, R Riemsma, N Woolacoot, J Glanville.
Opportunities for Bayesian analysis in evaluation of health-care interventions David Spiegelhalter MRC Biostatistics Unit Cambridge
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
International Auditing and Assurance Standards Board Accounting Estimates, Including Fair Value Accounting Estimates, and Related Disclosures ISA Implementation.
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
A Role for Decision Analysis in PHIAC? Mark Sculpher Centre for Health Economics University of York.
Elicitation Some introductory remarks by Tony O’Hagan.
Cost-Effectiveness Analyses in the UK - Lessons from the National Institute for Clinical Excellence Mark Sculpher Professor of Health Economics Centre.
Structural uncertainty from an economists’ perspective
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Dangerous Omissions – the Cost of Ignoring Decision Uncertainty Mark Sculpher Susan Griffin Karl Claxton Steve Palmer Centre for Health Economics, University.
The Use of Economic Evaluation For Decision Making: Methodological Opportunities and Challenges Mark Sculpher Karl Claxton Centre for Health Economics.
The Role of Trial-based Economic Evaluation in Health Care Decision Making Discussion Mark Sculpher Centre for Health Economics University of York iHEA,
Results 2 (cont’d) c) Long term observational data on the duration of effective response Observational data on n=50 has EVSI = £867 d) Collect data on.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Non-parametric Bayesian value of information analysis Aim: To inform the efficient allocation of research resources Objectives: To use all the available.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Copyright ©2011 Pearson Education, Inc. publishing as Prentice Hall
Identifying evidence for decision-analytic models Suzy Paisley DoH Research Scientist in Evidence Synthesis Consensus Working Group on the Use of Evidence.
DISCUSSION Alex Sutton Centre for Biostatistics & Genetic Epidemiology, University of Leicester.
Probability, Bayes’ Theorem and the Monty Hall Problem
GAAP PowerPoint #2. Understandability Decision Usefulness Relevance Predictive Value Feedback Value Timeliness Reliability Verifiability Neutrality Representational.
Their contribution to knowledge Morag Heirs. Research Fellow Centre for Reviews and Dissemination University of York PhD student (NIHR funded) Health.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Dr. Gary Blau, Sean HanMonday, Aug 13, 2007 Statistical Design of Experiments SECTION I Probability Theory Review.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
UKPopNet Workshop 1 Undertaking a Systematic Review Andrew S. Pullin Centre for Evidence-Based Conservation University of Birmingham, UK.
Decision making Under Risk & Uncertainty. PAWAN MADUSHANKA MADUSHAN WIJEMANNA.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
1 Demand for Repeated Insurance Contracts with Unknown Loss Probability Emilio Venezian Venezian Associates Chwen-Chi Liu Feng Chia University Chu-Shiu.
Statistical Decision Theory Bayes’ theorem: For discrete events For probability density functions.
PANEL SESSION: MODELLING HETEROGENEITY IN COST-EFFECTIVENESS ANALYSIS Modelling variation for decision making Mark Sculpher, PhD Centre for Health Economics,
Matching Analyses to Decisions: Can we Ever Make Economic Evaluations Generalisable Across Jurisdictions? Mark Sculpher Mike Drummond Centre for Health.
Course: Research in Biomedicine and Health III Seminar 5: Critical assessment of evidence.
“New methods in generating evidence for everyone: Can we improve evidence synthesis approaches?” Network Meta-Analyses and Economic Evaluations Petros.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
Outline Historical note about Bayes’ rule Bayesian updating for probability density functions –Salary offer estimate Coin trials example Reading material:
City University notes AJ Fischer October Nancy’s Questions Q1Different people present material with different cost perspectives? AWith all such.
Methods of Assigning Probabilities l Classical Probability; l Empirical Probability; and l Subjective Probability l P (A) = N(A) / N l P (X) = ƒ (X) /
 Why does environmental policy differ across countries?  Why doesn’t science necessarily lead to convergent outcomes?  What is the relationship of science.
Benjamin Kearns, The University of Sheffield
Cost effectiveness Analysis: Valuing Health; Valuing Research!
Campbell Collaboration Colloquium 2013
Health care decision making
CS 594: Empirical Methods in HCC Introduction to Bayesian Analysis
CS639: Data Management for Data Science
Presentation transcript:

Trial Based Economic Evaluation: Just Another Piece Of Evidence Claxton K Department of Economics and Centre for Health Economics, University of York, UK

Is the purpose of evaluation to inform decisions? What are the decisions? What is required? Which evidence is relevant? Does uncertainty matter? What is the role of trials? Are there any dangers?

What decisions? Given existing evidence: –Which interventions/strategies should be implemented? –For which patient/population groups? –For what type of indications/settings? Is further evidence required to support decisions? –What type of evidence –What type of studies –For which patient groups –How much evidence Delay implementation until the evidence is available?

So what’s required? –Joint distribution of cost and outcomes –For all alternative interventions/strategies –Explore the full range of clinical policies –For range of patient groups –In the relevant decision context –Over an appropriate time horizon

Should we consider all the evidence? Should social decision making consider all the evidence of relative effect? –Central tenant of EBM –Expected cost and outcomes –Characterisation of the uncertainty Should we compare all alternative interventions or only the selection included in a particular study? Should we also consider all the evidence for other parameters? Should we consider both direct and indirect evidence for all parameters?

Direct and indirect evidence? ABCD 1 xx 2 xx 3 xx 4 xx 5 xx 6 xx 7 xx Alternative interventions RCTs Synthesis 1 and 2 But compare all interventions? –Pair wise comparisons? –Use all the information –Estimate joint posterior LOR with correlations ABCD 1 xx 2 xx

Direct and indirect evidence? A B+C B C A+B+C A+BA+C -Estimates of parameter values -Uncertainty surrounding estimates -Correlations between parameters

Does decision uncertainty matter? Is an assessment of the consequences of decision uncertainty necessary for rational (expected value) decision making? -Is a characterisation of decision uncertainty a prerequisite for an assessment (formal or informal) of its consequences? -Does this require a synthesis of all evidence from a variety of sources?

Some examples from NICE Implications for research prioritisation

Can any single study provide a basis for decision making? Should we adopt a technology? Is further evidence required? When would a trial be sufficient basis –Trial follow-up and time horizon identical –All relevant comparators included as arms –Patients and practice relevant to decision-making context –All parameters estimated –Only source of evidence for all parameters

So what is the role of trials? As measurement –Particularly parameters subject to selection bias –Input to the synthesis of all evidence Implications for design –Useful for synthesis –Pragmatic trials (what is exchangeable)? Implications for reporting of evaluations –ICERs and certainly CEACs make little sense –Value of information without synthesis makes no sense

Do we need economic trials? Is Peto right? Its an empirical question Value of a trial updating all parameters

Do we need economic trials? Is Peto right? Its an empirical question Value of a portfolio of studies

Why trial based evaluation? Historical dominance of frequentist analysis –Probability is the relative frequency of repeated events –Traditional Inferential rules Fully Bayesian decision theoretic analysis –Priors based on synthesis of accumulated evidence –Specification of the loss function (decision framework)

Leon Trotsky, Preface to The History of the Russian Revolution Entirely exceptional conditions, independent of the will of persons or parties, are necessary in order to tear off the fetters of conservatism and bring the masses to insurrection The masses go into revolution not with a preprepared plan of social reconstruction, but with a sharp feeling that they cannot endure the old regime Leon Trotsky, Preface to The History of the Russian Revolution